Health Catalyst Inc

Health Catalyst Inc(HCAT)の株式分析

$1.500

-0.085 (-5.66%)終値時点

Loading chart…
高値
1.590
始値
1.590
出来高加重平均価格
1.51
出来高
336.35K
時価総額
357.16M
安値
1.450
売買代金
509.00K
EV/EBITDA(TTM)
6.09

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

www.healthcatalyst.com

AI分析 of Health Catalyst Inc (HCAT)

売り

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

バリュエーション指標

Health Catalyst Inc(HCAT)の現在の予想PERは10.00で、5年平均は-7.88です。

予想PER

適正
5年平均 P/E
-7.88
現在のP/E
10.00
割高
103.22
割安
-118.99

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-53.03
現在のEV/EBITDA
6.09
割高
98.36
割安
-204.42

予想PSR

適正
5年平均 P/S
1.83
現在のP/S
0.58
割高
3.43
割安
0.24

Alphio AI による HCAT の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%HCAT

$4.94

シナリオ価格

基

基本

基本 · 50%HCAT

$4.25

シナリオ価格

弱

弱気

弱気 · 25%HCAT

$4.22

シナリオ価格

HCAT を保有するクジラ

F

First Light Asset Management, LLC

+ を保有HCAT

+0.00%

3か月リターン

イベントタイムライン

2026-09-08 (ET)

09:00:00

Health Catalyst Appoints Simeon Kohl as CEO

2026-08-06 (ET)

17:30:00

Health Catalyst Closes Sale of Vitalware for $147 Million

17:00:00

Company Reports Q2 Revenue of $70.49M, Exceeding Expectations

17:00:00

Sees FY26 Adjusted EBITDA of $18M to $18.5M

17:00:00

Sees Q3 Adjusted EBITDA of $0-$500K

ニュース

HCAT のよくある質問 — Alphio AI が回答

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements. It operates in the Technology sector (SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ET industry).

Health Catalyst Inc is not a good buy right now. The current price is $1.58, which is significantly below the 52-week high of $3.36, indicating a decline of 53.0%. Additionally, the RSI is at 34.34, suggesting that the stock is oversold. The company has reported substantial losses, with a net income of -$111 million in Q1 2026 and -$40.5 million in Q2 2026, which raises concerns about its profitability. The main risk is the ongoing uncertainty around client churn and potential down-sell risks, as highlighted by analyst downgrades.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める